News from immunocellular therapeutics, ltd. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 28, 2021, 06:00 ET ImmunoCellular Therapeutics Announces Application for Continued Public Quoting on the Over-the-Counter (OTC) Market

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (OTC: IMUC), today announced that the Company has taken steps to comply with amended Rule...

Jul 02, 2020, 16:05 ET ImmunoCellular Therapeutics Announces Results of Special Meeting of Stockholders Held June 26, 2020

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (OTC: IMUC), today announced that, based on the vote count following the Special Meeting of...

Oct 16, 2019, 16:05 ET ImmunoCellular Therapeutics Announces Settlement of Derivative Action Lawsuit

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (OTC: IMUC), today announced that pursuant to an Order of the Superior Court of California,...

Aug 28, 2019, 16:05 ET ImmunoCellular Therapeutics Announces Completion of Asset Purchase Transaction with Private Biotechnology Company

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (OTC: IMUC) today announced receipt of payment of $500,000 in conjunction with the completion of ...

Jul 16, 2019, 16:05 ET ImmunoCellular Therapeutics Announces Asset Purchase Agreement with Private Biotechnology Company

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (OTC: IMUC), today announced an agreement with a privately held biotechnology company (the...

Oct 17, 2018, 06:00 ET ImmunoCellular Announces Receipt of Notice of Noncompliance with The NYSE American Continued Listing Standards

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC) today announced that on October 16, 2018, the Company received notice from ...

Oct 15, 2018, 16:05 ET ImmunoCellular Therapeutics Announces Delisting and Deregistration of Common Stock and Listed Common Stock Warrants

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC) today notified the NYSE American of its intention to voluntarily withdraw...

Aug 13, 2018, 16:05 ET ImmunoCellular Therapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC), a biotechnology company developing immunotherapies for the treatment of...

Jul 19, 2018, 06:00 ET ImmunoCellular Therapeutics Announces Agreement on Terms of Settlement of Federal Class Action Shareholder Lawsuit

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (NYSE American: IMUC), a biotechnology company developing immunotherapies for...

May 14, 2018, 04:05 ET ImmunoCellular Therapeutics Announces First Quarter 2018 Financial Results

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC) today announced financial results for the first quarter ended March 31,...

Mar 26, 2018, 06:00 ET ImmunoCellular Therapeutics Receives Audit Opinion with Going Concern Explanation

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC) today announced that, as previously disclosed in its Annual Report on Form ...

Feb 22, 2018, 06:00 ET ImmunoCellular Therapeutics Announces Review of Strategic Alternatives

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC), a biotechnology company developing immunotherapies for the treatment of...

Feb 13, 2018, 06:00 ET ImmunoCellular Therapeutics Announces Update on Financial Condition

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC), a biotechnology company developing immunotherapies for the treatment of...

Dec 13, 2017, 15:05 ET ImmunoCellular Therapeutics Achieves Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the Company) (NYSE American: IMUC) announced today that it has achieved a key milestone in its ...

Nov 22, 2017, 05:00 ET ImmuncoCellular Therapeutics to Present at the 10th Annual LD Micro Main Event on December 7, 2017

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC), a biotechnology company developing immunotherapies for the treatment of...

Nov 21, 2017, 15:05 ET ImmunoCellular Therapeutics Announces Third Quarter 2017 Financial Results

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC) today announced financial results for the third quarter 2017. Anthony J....

Nov 17, 2017, 05:00 ET ImmunoCellular Therapeutics to Report Third Quarter 2017 Financial Results on November 21, 2017

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that it plans to report third quarter 2017 financial results on ...

Oct 03, 2017, 06:00 ET ImmunoCellular Therapeutics to Present at the Lytham Partners Virtual Investor Conference on October 11, 2017 at 2:00pm ET

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC), a biotechnology company developing immunotherapies for the treatment of cancer ...

Sep 13, 2017, 16:05 ET ImmunoCellular Therapeutics Announces NYSE MKT Acceptance of its Plan of Compliance

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (NYSE MKT: IMUC) today announced that the NYSE MKT LLC (the "NYSE MKT") has...

Aug 23, 2017, 16:05 ET ImmunoCellular Therapeutics Provides Business Update on Research and Development Programs and Future Strategy

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) announced today that it plans to continue strategies to refocus and reallocate...

Aug 14, 2017, 18:00 ET ImmunoCellular Therapeutics Announces Second Quarter 2017 Financial Results

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced financial results for the second quarter 2017. For the quarter...

Jul 18, 2017, 06:00 ET ImmunoCellular Therapeutics Announces Pricing of Public Offering of Convertible Preferred Stock and Warrants

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced the pricing of an underwritten public offering of 5,000 shares...

Jun 29, 2017, 16:05 ET ImmunoCellular Therapeutics Receives Notice from NYSE MKT for Noncompliance with Continued Listing Standards

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced it has received notification from the NYSE MKT LLC that the...

Jun 21, 2017, 06:00 ET ImmunoCellular Therapeutics Provides Update on Strategic Review and Decision to Suspend Further Patient Randomization for ICT-107 Phase 3 Trial

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today provided an update on the strategic review of its financing and...

Jun 12, 2017, 16:05 ET ImmunoCellular Therapeutics to Present at Marcum MicroCap Conference on June 15, 2017

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Anthony J. Gringeri, PhD, President and Chief Executive...